From Europe

EORTC Board for 1997–2000

Last month, the senior positions of the Board of The European Organisation for Research and Treatment of Cancer (EORTC) were reported.

The following appointments were announced: the new President, Professor Jean-Claude Horiot; Vice-President, Professor Allan T. van Oosterom; Secretary General, Dr Alexander M. M. Eggermont; Treasurer of the EORTC, Professor John Double; and the new Director of the EORTC Data Centre, Dr Patrick Therasse.

This issue announces the new chairmen of the treatment Division, Research Division, Education and Training Division. Protocol Review Committee, Quality Control Committee, Scientific Audit Committee, New Drug Development and Coordinating Committee.

Chairman, Research Division: Maurizio D'Incalci

Maurizio D'Incalci was born in Milan in 1952 and obtained his medical degreecum Laude from the University of Milan in 1977. After specialisation in pharmacology at the Mario Negri Institute of Milan and in oncology at the University of Genova, he worked in the Laboratory of Molecular Pharmacology of the National Cancer Institute in Bethesda, Maryland, U.S.A.

Since 1986 he has been chief of the Laboratory of Cancer Chemotherapy at the Mario Negri Institute.

He is a member of the Societa Italiana di Cancerologia (SIC) and of the American Association for Cancer Research (AACR). He has been Pres-ident of the Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer (EORTC). From 1994 to 1997 he has been the Chairman of the New Drug Coordinating Development Committee. He is on the Steering Committee of EORTC-Cancer Research Campaign (CRC)-NCI for the co- ordination of the developmnet of new anticancer agents in Europe, U.K. and U.S.A.

He is on the editorial board of many international cancer related scientific journals and is the Associate Editor for Basic Research of *Annals of Oncology*.

He is author of more than 200 papers of cancer chemotherapy published in peerreviewed International Journals and of several chapters on books of Cancer Chemotherapy.

Chairman, Treatment Division: Dr Martine J. Piccart


Dr Martine J. Piccart obtained her medical degree in 1978, La Plus Grande Fleuris Distinction, Prix Mercier, Universite Libre de Bruxelles. She gained her PhD in 1992. Between 1978 and 1983 she was Assistant in the Department of Internal Medicine, Jules Bordet Institute (1978-1980 and 1981-1983) and in the Department of Internal Medicine, Sint-Peter Hospital (1980-1981), Brussels, Belgium. In 1983-1985 she was Clinical Research Associate in the Division of Oncology, New York University Medical Center, New York. From 1985 she was Assistant in the Department of Internal Medicine, Jules Bordet Institute, Brussels, Belgium.

Since 1989 she has been Head of the Chemotherapy Unit, Jules Bordet Institute.

She was Secretary of the Gynaecological Cancer Cooperative Group of the EORTC from 1989 to 1996, and Chairman of the Investigational Drug Branch for Breast Cancer of the EORTC (since 1991). She was also Chairman of the Breast Cancer Cooperative Group of the EORTC (1994–1997). Dr Piccart has had 95 articles published.



Chairman, Rosean h Dicision



Chairman Try, theo y Division

Chairman, Education and Training Division: J.M.A. Whitehouse, Southampton

Chairman, Protocol Review Committee: M. Aapro, Genolier

Chairman, Quality Control Committee: P.H.M. de Mulder, Nijmegen

Scientific Audit Committee, D.K.Hossfeld, Hamburg

New Drug Development and Coordinating Committee: J. Verweij, Rotterdam